Testosterone enanthate

Medical uses

Testosterone enanthate is used primarily in androgen replacement therapy. It is the most widely used form of testosterone in androgen replacement therapy. The medication is specifically approved, in the United States, for the treatment of hypogonadism in men, delayed puberty in boys, and breast cancer in women. It is also used in masculinizing hormone therapy for transgender men.

Side effects

Side effects of testosterone enanthate include virilization among others. Approximately 10 percent of testosterone enanthate will be converted to 5α-dihydrotestosterone in men without endocrine disease or taking medication that disrupts this conversion, such as finasteride. 5α-Dihydrotestosterone (DHT) can promote masculine characteristics in both males and females. These masculine characteristics include: clitoral hypertrophy, androgenic alopecia, growth of body hair and deepening of the vocal cords. Dihydrotestosterone also plays an important role in male sexual function and may also be a contributing factor of ischemic priapism in males as shown in a study conducted on the use of finasteride to treat ischemic priapism in males. Testosterone enanthate can also lead to an increase in IGF-1 and IGFBP. Testosterone enanthate can also be converted to estradiol (E2) by the aromatase enzyme, which may lead to gynecomastia in males. Aromatase inhibitors, such as anastrozole, letrozole, exemestane, etc., can help to prevent the subsequent estrogenic activity of testosterone enanthate metabolites in the body.

Pharmacology

Pharmacodynamics

Testosterone enanthate is a prodrug of testosterone and is an androgen and anabolic–androgenic steroid (AAS). That is, it is an agonist of the androgen receptor (AR).

Testosterone enanthate is converted by the body to testosterone that has both androgenic effects and anabolic effects; still, the relative potency of these effects can depend on various factors and is a topic of ongoing research. Esterase enzymes break the ester bond in testosterone enantate, releasing free testosterone and enanthic acid through hydrolysis. This process ensures a sustained release of free bioavailable and bioactive testosterone in the body. Testosterone can either directly exert effects on target tissues or be metabolized by the 5α-reductase enzymes into 5α-dihydrotestosterone (DHT) or aromatized to estradiol (E2). Aromatization in this context is the process where testosterone is converted to estradiol (E2) by the enzyme aromatase (CYP19A1 in humans). This conversion involves changing the structure of testosterone to include an aromatic ring A of a steroid nucleus, making it an estrogen, a so-called female hormone, which plays various roles in the body, such as regulating reproductive functions and bone density. If not aromatized (not converted into an estrogen), both testosterone and DHT are bioactive and bind to an androgen receptor; however, DHT has a stronger binding affinity than testosterone and may have more androgenic effect in certain tissues (such as prostate gland, skin and hair follicles) at lower levels.

Pharmacokinetics

Testosterone enanthate has an elimination half-life of 4.5 days and a mean residence time of 8.5 days when used as a depot intramuscular injection. It requires frequent administration of approximately once per week, and large fluctuations in testosterone levels result with it, with levels initially being elevated and supraphysiological. When testosterone enanthate is dissolved in an oil (such as castor oil), the oil acts as a depot, or reservoir, that slowly releases the drug into the bloodstream. This slow release is due to the oil's viscosity and the gradual breakdown of the ester bond by esterase enzymes. The oil creates a barrier that slows the diffusion of testosterone enanthate into the surrounding tissues, resulting in a more controlled and prolonged release compared to injecting pure testosterone enanthate. The rate at which testosterone enanthate is released from oils can vary based on the oil's viscosity and other properties such as drug solubility in the oil.

Chemistry

Testosterone enanthate, or testosterone 17β-heptanoate, is a synthetic androstane steroid and a derivative of testosterone. It is an androgen ester; specifically, it is the C17β enanthate (heptanoate) ester of testosterone.

History

Testosterone enanthate was described as early as 1952 and was first introduced for medical use in the United States in 1954 under the brand name Delatestryl.

Society and culture

Generic names

Testosterone enanthate is the generic name of the drug and its and . It has also referred to as testosterone heptanoate.

Brand names

Testosterone enanthate is marketed primarily under the brand name Delatestryl.

It is or has been marketed under a variety of other brand names as well, including, among others:

• Andro LA
• Andropository
• Cypionat
• Cypoprime
• Depandro
• Durathate
• Everone
• Testocyp
• Testostroval
• Testrin
• Testro LA
• Xyosted
• pharmaqo labs

Availability

Testosterone enanthate is available in the United States and widely elsewhere throughout the world. Testosterone enanthate (testosterone heptanoate) is often available in concentrations of 200 mg per milliliter of fluid.

Legal status

Testosterone enanthate, along with other AAS, is a schedule III controlled substance in the United States under the Controlled Substances Act and a schedule IV controlled substance in Canada under the Controlled Drugs and Substances Act.

Research

As of October 2017, an auto-injection formulation of testosterone enanthate was in preregistration for the treatment of hypogonadism in the United States.

Xyosted

On October 1, 2018, the U.S. Food and Drug Administration (FDA) announced the approval of Xyosted. Xyosted, a product of Antares Pharma, Inc., is a single-use disposable auto-injector that dispenses testosterone enanthate. Xyosted is the first FDA-approved subcutaneous testosterone enanthate product for testosterone replacement therapy in adult males.

References

References

1. (26 July 2012). "Testosterone: Action, Deficiency, Substitution". Cambridge University Press.
2. (13 January 2010). "Andrology: Male Reproductive Health and Dysfunction". Springer Science & Business Media.
3. (2011). "Anabolics". Molecular Nutrition Llc.
4. (April 2017). "Testosterone therapy for women". The Lancet. Diabetes & Endocrinology.
5. (2001). "Principles and Practice of Endocrinology and Metabolism". Lippincott Williams & Wilkins.
6. (2007). "The Leydig Cell in Health and Disease". Humana Press.
7. (June 2008). "Pharmacology of anabolic steroids". British Journal of Pharmacology.
8. (April 2016). "Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement". The Journal of Clinical Endocrinology and Metabolism.
9. (2022). "Testosterone Therapy with Subcutaneous Injections: A Safe, Practical, and Reasonable Option". The Journal of Clinical Endocrinology & Metabolism.
10. "Testosterone enantate - Knowledge and References".
11. (2004). "Testosterone replacement therapy: Current trends and future directions". Human Reproduction Update.
12. (2021). "Marine Bacterial Esterases: Emerging Biocatalysts for Industrial Applications". Applied Biochemistry and Biotechnology.
13. "Testosterone Enanthate raw powder (CAS 315-37-7) ≥98% {{!}} AASraw". aasraw.
14. "DELATESTRYL Package Insert". Indevus Pharmaceuticals, Inc..
15. (28 July 2017). "DHT (dihydrotestosterone): What is DHT's role in baldness?".
16. (1995). "Testosterone increases insulin-like growth factor-1 and insulin-like growth factor-binding protein". Annals of Clinical and Laboratory Science.
17. (March 2015). "Management of Recurrent Ischemic Priapism 2014: A Complex Condition with Devastating Consequences". Sexual Medicine Reviews.
18. (February 2006). "Aromatase-independent testosterone conversion into estrogenic steroids is inhibited by a 5 alpha-reductase inhibitor". The Journal of Steroid Biochemistry and Molecular Biology.
19. (2017). "Thyroid Diseases".
20. (2002). "Anabolic steroids". Recent Prog Horm Res.
21. (2017). "Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels". Endocrine Reviews.
22. "Archived copy".
23. "Testosterone enanthate".
24. "Archived copy".
25. (2012). "Long Acting Injections and Implants". Springer.
26. (2019). "Investigation of Controlled Release Molecular Mechanism of Oil Phase in Spilanthol Emulsion: Development and in Vitro, in Vivo Characterization". AAPS PharmSciTech.
27. (1971). "Influence of HLB values of surfactants on ephedrine release from emulsified liquid systems". Journal of Pharmaceutical Sciences.
28. (14 November 2014). "The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies". Springer.
29. (January 2000). "Index Nominum 2000: International Drug Directory". Taylor & Francis.
30. (1952). "Festschrift zum 75. Geburtstag". Springer.
31. (2007). "Testosterone Enanthate". William Andrew Publishing.
32. (6 December 2012). "Concise Dictionary of Pharmacological Agents: Properties and Synonyms". Springer Science & Business Media.
33. (October 1, 2018). "Testosterone".
34. "Testosterone cypionate profile and most popular brands in USA".
35. "Drugs@FDA: FDA Approved Drug Products". United States Food and Drug Administration.
36. "Testosterone enanthate". Drugbank.
37. (21 December 2006). "Drug Abuse Handbook, Second Edition". CRC Press.
38. (5 August 2016). "Pharmacology for Canadian Health Care Practice". Elsevier Health Sciences.
39. (February 5, 2018). "Testosterone enanthate auto-injection - Antares Pharma".
40. "Antares Receives Fda Approval of Xyostedtm (Testosterone Enanthate) Injection for Testosterone Replacement Therapy in Adult Males".